With $7.8B takeout, Gilead sees Arcellx’s cell therapy as competitive with J&J’s
Gilead takes full control, economics around registrational treatment for multiple myeloma as it prepares to take on Carvykti
More than three years after forging a partnership with Arcellx around a cell therapy for multiple myeloma, Gilead is acquiring the biotech for $7.8 billion up front, giving it full control of a registrational treatment that could have safety and manufacturing advantages over its competitors.
The deal deepens the commitment of Gilead Sciences Inc. (NASDAQ:GILD) to products and platforms developed by Arcellx Inc. (NASDAQ:ACLX), including lead program anitocabtagene autoleucel, a CAR T cell therapy known informally as anito-cel. The companies’ initial partnership in December 2022, which they have since broadened, put the commercial and operational strength of Gilead and its Kite Pharma Inc. unit behind anito-cel, while preserving Arcellx’s independence...